Skip to main content

Advertisement

SpringerLink
Log in

Current research in nuclear medicine and molecular imaging: highlights of the 23rd Annual EANM Congress

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

The most recent research developments in nuclear medicine and molecular imaging were presented at the 2010 Annual Congress of the EANM. This review summarizes some of the most relevant contributions made in the fields of oncology, cardiovascular science, neurology and psychiatry, technological innovation and novel tracers. Presentations covered basic and clinical research in nuclear medicine and molecular imaging, and diagnostic and therapeutic applications of radioisotopes and radiopharmaceuticals on a global scale. The results reported demonstrate that investigative strategies using nuclear medicine techniques facilitate effective diagnosis and management of patients with most prevalent disease states. At the same time novel tracers and technologies are being explored, which hold promise for future new applications of nuclear medicine and molecular imaging in research and clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19
Fig. 20
Fig. 21
Fig. 22
Fig. 23
Fig. 24
Fig. 25
Fig. 26
Fig. 27
Fig. 28
Fig. 29
Fig. 30

Similar content being viewed by others

References

  1. Langsteger W. EANM 2010—Welcome to Vienna! Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:S183–4.

    Article  Google Scholar 

  2. European School of Nuclear Medicine Continuing Medical Education at the Annual Congress of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:S191–7.

    Google Scholar 

  3. Aukema TS, Kappers I, Valdés-Olmos RA, Teerstra HJ, Schaake EE, Van Tinteren H, et al. 18F-FDG PET/CT and diagnostic CT for the prediction of histopathologic treatment response after epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with resectable NSCLC. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP228.

    Google Scholar 

  4. Capriotti G, Tabbi L, Pizzichini P, Prosperi D, Durante S, Papa A, et al. Radiofrequency ablation in lung cancer: comparison between contrast-enhanced CT and PET/CT. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP344.

    Google Scholar 

  5. Apostolopoulos DJ, Hohenberger P, Roumia S, Dimitrakopoulou-Strauss A, Strauss LG. The value of parametric F-18-FDG-PET images for the detection of liver metastases in patients with gastrointestinal stromal tumors under anti-proliferative and anti-angiogenic therapy. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP027.

    Google Scholar 

  6. Picchio M, Giovannini E, Landoni C, Passoni P, Crivellaro C, Reni M, et al. Role of FDG PET-CT in HTT treatment planning for patients with locally advanced pancreatic cancer: selection and treatment monitoring. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP154.

    Google Scholar 

  7. Goetze L, Prassad V, Kaemmerer D, Lupp A, Schulz S, Hommann M, et al. Immunohistochemical validation of somatostatin-receptor PET/CT as in-vivo method for quantification of receptor density in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP392.

    Google Scholar 

  8. Volterrani D, Filidei E, Cosio S, Grosso M, Manca G, Paglianiti I, et al. Impact of PET/CT with FDG on the clinical management of patients with ovarian cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP557.

    Google Scholar 

  9. Antunovic L, Cimitan M, Borsatti E, Baresic T, Tatta R, Sorio R, et al. 18F-FDG PET/CT for the detection of recurrent epithelial ovarian carcinomas: correlation with histology, serum Ca125 assay and conventional radiological modalities. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP556.

    Google Scholar 

  10. Han S, Shaikh G, Reed N. F18-FDG PET/CT in the staging and the assessment of suspected relapse in cervical cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP559.

    Google Scholar 

  11. Fiebrich H, de Jong JR, Kema IP, Koopmans K, Sluiter W, Dierckx TA, et al. Total 18F-DOPA PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP585.

    Google Scholar 

  12. Montravers F, Nataf V, Bologova S, Calzada M, Maurel G, Kerrou K, et al. Comparison of FDOPA(18F) and DOTATOC (68Ga) PET/CT for detection of ileal carcinoid tumours. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP586.

    Google Scholar 

  13. Cheebsumon P, van Velden FH, De Ruysscher D, van Elmpt W, Yaqub M, Hoekstra OS, et al. Assessment of tumour volume in lung cancer: PET versus CT based methods. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP343.

    Google Scholar 

  14. Christensen CB, Berthelsen A, Loft A. Impact on treatment using PET/CT for radiotherapy planning. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP222.

    Google Scholar 

  15. Kolodziejczyk M, Kepka L, Zawadzka A, Dziuk E, Szalus N, Bujko K, et al. Prospective study on the role of 18F-FDG PET-CT on planning of the radiotherapy with elective nodal irradiation for non-small cell cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP223.

    Google Scholar 

  16. Jinnouchi S, Tateno R, Ueno I, Tanabe H. Usefulness of 4D PET/CT imaging in lung lesions with respiratory gated scan. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:PW031.

    Google Scholar 

  17. Sen F, Akpinar AT, Ozkan L, Yildrim N, Ogur U, Demirtas YO, et al. Radiation-induced lung injury on 18F-FDG PET/CT: analysis of patterns of FDG uptake versus CT, and correlation with radiotherapy dose parameters in lung cancer patients. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP225.

    Google Scholar 

  18. Baudino B, D’Agata F, Castellano G, Caroppo P, Gauda S, Manfredi M, et al. Chemotherapy effects on cerebral glucose metabolism at rest. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP229.

    Google Scholar 

  19. Sami M, Joshi K, Raman V, Burkill G, Miles KA, Dizdarevic S. Imaging assessment of FDG-avid lymphomas. Is diagnostic CT a necessary adjunct to PET-CT? Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP470.

    Google Scholar 

  20. Rizvi SN, Zijlstra J, Riphagen II, Langendijk JA, Hoekstra OS, Raijmakers PG. Meta-analysis of progression-free survival upon interim FDG PET results during first line chemotherapy in Hodgkin’s disease. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP101.

    Google Scholar 

  21. Kluge R, Purz S, Korholz D, Mauz-Korholz C, Hasenclever D, Krausse A, et al. FDG-PET for diagnosing bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP471.

    Google Scholar 

  22. Fonti R, Larobina M, De Luca S, Fabriccini R, Catalano L, Pace L, et al. Metabolic tumour volume assessed by 18F-FDG-PET/CT in the evaluation of plasma cell mass and prediction of outcome in patients with multiple myeloma. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP113.

    Google Scholar 

  23. Gupta A, Patel CD, Kumar R, Pandey AK, Bakhshi S, Malhotra A, et al. Evaluation of treatment response using whole body metabolic tumor burden estimated by FDG PET/CT images in pediatric lymphoma. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:TP019.

    Google Scholar 

  24. Herrmann K, Erkan M, Siveke J, Dobritz M, Schuster T, Krause B, et al. Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography and FDG-PET/CT for the detection of pancreatic cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP153.

    Google Scholar 

  25. Goldenberg DM, Kraeber-Bodere F, Morschhauser F, Petillon M, Huglo D, Meller J, et al. Final results of a Phase I/II trial of fractionated radioimmunotherapy with anti-CD22 90Y-epratuzumab tetraxetan in relapsed/refractory non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP230.

    Google Scholar 

  26. Goldenberg DM, Ocean AJ, Goldsmith SJ, Guarino MJ, Manzone T, Pennington KL, et al. Fractionated radioimmunotherapy combined with low-dose gemcitabine shows enhanced cumulative radiation delivery and therapeutic effects in advanced pancreatic cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP231.

    Google Scholar 

  27. Malek E, Ferrer L, Bardies M, Bodet C, Kraeber F, Huglo D, LeGouill S, et al. Dosimetry for fractionated Zevalin treatment as an initial therapy of follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP232.

    Google Scholar 

  28. Kletting P, Reske SN, Glatting G. Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP234.

    Google Scholar 

  29. Fuccio C, Castellucci P, Santi I, Nanni C, Allegri V, Montini G, et al. Usefulness of 11C-choline PET/CT as a first diagnostic procedure in patients with biochemical relapse and PSA level lower than 1.5 ng/ml. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP411.

    Google Scholar 

  30. Schroeder R, van Weerden W, Krenning EP, Bangma CH, Grievink-de Ligt C, Berndsen S, et al. Gastrin-releasing peptide receptor-based imaging using bombesin analogues is superior to choline-based metabolic targeting for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP567.

    Google Scholar 

  31. Hillier SM, Maresca KP, Merkin R, Tesson M, Barrett JA, Mairs R, et al. Inhibition of human prostate cancer growth by targeting prostate specific membrane antigen using an I-131 labeled small molecule inhibitor. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP552.

    Google Scholar 

  32. Groheux D, Hindie E, Vercellino L, Berenger N, Giachetti S, Porcher R, et al. 18F-FDG uptake in breast cancer: correlation with clinico-pathological and biological prognostic markers. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP279.

    Google Scholar 

  33. Rousseau C, Campion L, Pallardy A, Campone M, Testard A, Ferrer L, et al. FDG PET can be useful to predict survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP282.

    Google Scholar 

  34. Evangelista L, Cervino A, Gregianin M, Baretta Z, Saladini G, Muzzio P. Comparison between 18F-FDG PET/CT and computed tomography for prognostic evaluation in patients with breast invasive ductal cancer. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP284.

    Google Scholar 

  35. Vroonland C. Dedicated mini PET system for breast screening: a technologist’s perpsective. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:T015.

    Google Scholar 

  36. Spanu A, Chessa F, Sanna D, Cottu P, Manca A, Nuvoli S, et al. Molecular breast imaging with a high resolution dedicated breast camera in the detection of ductal carcinoma in situ: a correlation with mammography and histologic subtype. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:PW061.

    Google Scholar 

  37. Nagarajah J, Hartung V, Jentzen W, Antoch G, Hahn S, Bockisch A, et al. Detection of thyroid remnant and lymph node metastases with iodine-124 in differentiated thyroid carcinoma: PET alone vs. fused PET/MR and integrated PET/CT. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP022.

    Google Scholar 

  38. Putzer D, Kross A, Gabriel M, Kendler D, Dobrozemsky G, Bale R, et al. 68Ga-DOTA-Tyr3-octreotide PET in thyroid cancer patients compared to 18F-FDG PET and radioiodine-avidity. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP103.

    Google Scholar 

  39. Biko J, Rainers C, Kreissl M, Demidchik Y, Drozd V. Spontaneous course of disease in pediatric patients with thyroid cancer and pulmonary metastases after incomplete elimination of the metastases by high-dose radioiodine therapy: results of a ten-year follow-up. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:PW040.

    Google Scholar 

  40. Ghilardi A, Medolago G, Bianchi C, Poli G. How to improve gated-SPECT myocardial perfusion imaging using a high resolution matrix [128×128 pxls] and scatter correction: preliminary results. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:T03.

    Google Scholar 

  41. Pena H, Cantinho G, Pereira L, Magno I, Graça A, Wilk M, et al. XPRESS—half-dose/half-time GATED cardiac SPECT validation. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP034.

    Google Scholar 

  42. Dey T, Wieczorek H, Bippus R, Backus B, Romijn L, Verzijlbergen F, et al. A technetium-rest thallium-stress protocol for cardiac SPECT imaging: phantom and patient studies. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP035.

    Google Scholar 

  43. Bakker ED, Harms HJ, Raijmakers PG, Hoekstra OS, Knaapen P, Lammertsma AA, et al. Motion-induced PET-CT misalignment does not affect absolute myocardial blood flow measured by O15-water. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP037.

    Google Scholar 

  44. Khorsand A, Sochor H, Schültz M, Karanikas G, Kletter K, Dudczak R, et al. Assessment of myocardial perfusion by dynamic C-11 acetate PET imaging: comparison of two methods of quantification. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP038.

    Google Scholar 

  45. Genovesi D, Giorgetti A, Gimelli A, Cannizzaro G, Giubbini R, Bertagna F, et al. Impact of the use of attenuation-correction in G-SPECT myocardial perfusion imaging interpretation: results of multicenter SPAG study. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:P203.

    Google Scholar 

  46. Timmer SAJ, Germans T, Goethe MJW, Russel IK, Lubberink M, ten Berg JM, et al. Coronary microvascular dysfunction in hypertrophic cardiomyopathy is related to contractile dysfunction independent from myocardial injury: a PET and CMR study. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP158.

    Google Scholar 

  47. Timmer SAJ, Knaapen P, Dijkmans PA, Germans T, Lubberink M, ten Berg JM, et al. Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP157.

    Google Scholar 

  48. De Rimini ML, Catalano M, Piccolo S, Borrelli G, Russo A, Allocca A, et al. Rubidium 82 Cardiac PET: the first Italian experience. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP582.

    Google Scholar 

  49. Farhad H, Dunet V, Allenbach G, Soubeyran V, Coendoz N, El Hakmaoui F, et al. Incremental prognostic value of myocardial blood flow quantification with Rb-82 cardiac PET in patients with known or suspected CAD. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP583.

    Google Scholar 

  50. Evangelista L, Acampa W, Daniele S, Xhoxhi E, De Rimini ML, Cittanti C, et al. Role of SPECT imaging over clinical data in the definition of likelihood of coronary artery disease in diabetic patients. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP420.

    Google Scholar 

  51. Acampa W, Evangelista L, Daniele S, Xhoxhi E, De Rimini ML, Cittanti C, et al. Impact of inducible ischemia by SPECT imaging on cardiac risk assessment in diabetic patients: results of a prospective multicenter trial. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP418.

    Google Scholar 

  52. Lindner O, Burchert W, Schaffers M. Myocardial perfusion scintigraphy 2008 in Germany: results of the 4th query. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP579.

    Google Scholar 

  53. Morbelli S, Drzezga A, Perneczky R, Frisoni G, Caroli A, Van Berckel BN, et al. Resting-state brain metabolic connectivity in amnestic MCI-AD converters and healthy controls. A joint project of the European Alzheimer’s disease consortium (EADC). Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP353.

    Google Scholar 

  54. Barthel H, Senda M, Luthardt J, Strick A, Yamane T, Sattler B, et al. Phase 1 trials on florbetaben β-amyloid brain PET in elderly normal controls. Influence of ethnic group, age, gender, and tracer mass dose. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP221.

    Google Scholar 

  55. Sabri O, Gertz HJ, Dressel S, Heusner I, Bartenstein P, Bürger K, et al. Results of a multicentre phase 2 trial to test florbetaben for β-amyloid brain PET in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP354.

    Google Scholar 

  56. Furumoto S, Okamura N, Fodero-Taviletti M, Mulligan R, Cappa R, Iwata R, et al. Fluorine-18 labeled PET probes for imaging of neurofibrillary tangles. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP052.

    Google Scholar 

  57. Kuzhuppyilly N, Rybczynska A, Visser A, van Waarde A, Elsinga P, Ishiwata K, et al. Sigma-1 receptors in healthy aging: brain receptor density in young and aged rats assessed with 11C-SA4503 and micro-PET. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP350.

    Google Scholar 

  58. Brust P, Deuther-Conrad W, Becker G, Fischer S, Hiller A, Østergaard Nielsen E, et al. In vivo binding of [18F]NS10743 on alpha7 nicotinic acetylcholine receptors in pig brain. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP351.

    Google Scholar 

  59. Di Giuda D, Fasano A, Camardese G, Cocciolillo F, Bruno I, Guidubaldi A, et al. Correlations between striatal dopamine transporter (DAT) availability and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP120.

    Google Scholar 

  60. Ziebell M, Andersen BB, Pinborg LH, Thomsen G, Hasselbalch SG, Karlsborg M, et al. Predictive value of [123I]PE2I SPECT DAT imaging in patientswith early signs of parkinsonism—a prospective study of 288patients. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP437.

    Google Scholar 

  61. Berti V, Polito C, Borghammer P, Ramat S, Mosconi L, de Leon M, et al. Cortical hypometabolism in untreated de novo Parkinson’s disease: comparison of different normalization procedures. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP122.

    Google Scholar 

  62. Tatsch K, Varrone A, Tossici-Bolt L, Dickson JC, Sera T, Darcourt J, et al. ENCDAT-European database pf I123-FP-CIT SPECT scans of healthy subjects: final results. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP440.

    Google Scholar 

  63. Doorduin J, de Vries EFJ, Willemsen TM, Dierckx R, Klein HC. Imaging of herpes virus activity in the central nervous system of schizophrenic patients. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP066.

    Google Scholar 

  64. Okazawa H, Isozaki M, Arai Y, Kiyono Y, Kudo T, Mori T, et al. Feasibility of [Cu-62]ATSM PET to delineate misery perfusion in patients with major cerebral arterial occlusive lesions. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP125.

    Google Scholar 

  65. Andersson JD, Farde L, Seneca N, Truong P, Wensbo D, McLeod D, et al. [11C]AZ11696415: characterization of a novel PET radioligand for in-vivo visualization of the mGlu5 receptor in the cynomolgus monkey brain. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP055.

    Google Scholar 

  66. Ooms M, Celen S, Verbruggen A, van Laere K, Bormans G. Synthesis and preliminary biological evaluation of [11C]-MP10 and its regio-isomer as potential radioligands for positronemission tomography imaging of phosphodiesterase-10A in the brain. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP054.

    Google Scholar 

  67. van Velden FHP, Cheebsumon P, Yaqub M, Hoekstra OS, Lammertsma A, Boellaard R. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous tumour FDG uptake in PET studies. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP362.

    Google Scholar 

  68. Kennedy JA, Yolisevsky G, Karry R, Przewloka K, Israel O, Frenkel A. Optimization of acquisition time for ultrafast parathyroid SPECT imaging using a solid state CZT camera. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP546.

    Google Scholar 

  69. Beyer T, Quick H, Herzog H, Bockisch A, Tellmann L. The effect of MR radiofrequency coils on PET quantification in whole-body PET/MR: results from a pseudo-PET/MR phantom study. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP133.

    Google Scholar 

  70. Schulz V, Solf T, Weissler B, Gebhardt P, Piemonte C, Fischer P, et al. Innovative technologies for simultaneous TOF PET/MR. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP130.

    Google Scholar 

  71. Ratib O, Willi J, Wissmeyer M, Steiner C, Allaoua M, Garibotto V, et al. Clinical application of whole-body hybrid PET-MR scanner in oncology. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP134.

    Google Scholar 

  72. Marsouvanidis PJ, Maina T, Krenning P, de Jong M, Nock T. [99mTc]SAR-G1: a new candidate for GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP174.

    Google Scholar 

  73. Knetsch P, Seidel G, Petrik M, Rangger C, Helbok A, Griessinger C, et al. Comparison of Ga-68 labelled RGD-peptides for imaging integrin alpha(ν)beta3 expression. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP308.

    Google Scholar 

  74. Yu Z, Herscheid JDM, Verbeek J, Helfrich W, Dierckx RA, de Jong IJ, et al. A novel 123I-cubane labelled bombesin for imaging GRP receptor-expressing prostate cancer cells. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP177.

    Google Scholar 

  75. Andralojc K, Brom M, Joosten L, Oyen W, Boerman O, Gotthardt M. In vivo visualization of transplanted islets in rat by SPECT with 111In-Exendin-3. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP614.

    Google Scholar 

  76. Toyohara J, Sakata M, Ishiwata K, Wu J, Ohba H, Tsukada H, et al. In vivo evaluation of carbon-11-labeled N-((S)-1-((S)-methylpiperidin-2-yl)ethyl)acetamide derivatives as a potential radioligands for glycine transporter 1. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:P124.

    Google Scholar 

  77. Köster U, Nikula T, Calzavara Y, Gerstenberg H, Juntunen P, Marx S, et al. Possibilities for supplementary 99Mo production at European high-flux reactors. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP303.

    Google Scholar 

  78. Nikula T, Köster U, Ponsard B, Zhernosekov K, Juntinen O, Nikula L. Reliable 99Mo/99mTc-generator based on medium-specific activity 99Mo. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP304.

    Google Scholar 

  79. Guerin B, Zyudin A, van Lier EJ, Lecomte R van Lier JE. Cyclotron production of technetium-99m. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP305.

    Google Scholar 

  80. Govignon AM, Bardiès M, Chouin N, Ferrer L, Hindorf C. Multiscale approach for beta absorbed dose calculations in targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP270.

    Google Scholar 

  81. Ahmadzadehfar H, Muckle M, Sabet A, Kuhl C, Biermann K, Haslerud T, et al. The significance of bremsstrahlung SPECT-CT of the abdomen after yttrium 90 microsphere selective internal radiation treatment (SIRT) in the early diagnosis of SIRT-induced extrahepatic side effects. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP373.

    Google Scholar 

  82. Aloj L, Aurillo M, Rinaldi V, Morelli G, Tesauro D, Breeman WA, et al. Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/Gastrin receptor binding peptides: a collaborative project under COST Action BM0607. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP404.

    Google Scholar 

  83. Ocak M, Rangger C, Klinger M, Kabasakal L, Decristoforo C, von Guggenberg E. Comparison and improvement of the metabolic stability of CCK-2 receptor targeting peptides, a collaborative projectunder COST BM0607. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP405.

    Google Scholar 

  84. Boerman OC, Laverman P, Joosten L, Eek A, Roosenburg S, Oyen WJ. Comparative biodistribution studies of 12 CCK2 receptor binding ligands in nude mice with CCK2R expressing tumors:a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP406.

    Google Scholar 

  85. Papakonstantinou K, Karfis I, Lyra M, Paphiti M, Stayraka A, Voros D, et al. Super-selective hepatic arterial infusions of Y-90-DOTA-TOC and/or Lu-177-DOTA-TATE in neuroendocrine liver metastases after selective catheterization of the hepatic artery and permanent port installation, previously treated with high doses of In-111-DTPA-Phe1-Octreotide. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP391.

    Google Scholar 

  86. Bodei L, Cremonesi M, Grana CH, Fazio N, Iodice S, Lombardo D, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the phase I-II Milan protocol. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP393.

    Google Scholar 

  87. Arbizu J, Miani C, Salvatori R, Geatti O, Golfieri R, Ezzidin S, et al. European multicentre evaluation of radioembolisation with 90Y-labelled resin microspheres: an analysis of safety and predictors for survival in hepatocellular carcinoma (HCC). Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP457.

    Google Scholar 

  88. Vanpouille C, Garcion E, Lacoeuille F, Lepareur N, Le Jeunel JJ, Benoît J, et al. Nanovectorized internal radiation therapy in a glioblastoma rat model. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP474.

    Google Scholar 

  89. Sowa-Staszczak A, Pach D, Stefańska A, Tomaszuk M, Mikołajczak R, Pawlak D, et al. Assessment of effectiveness and toxicity of the therapy with somatostatin analogue labelled 90Y-DOTATATE in patients with non-functional pancreatic neuroendocrine tumours (PNT). Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:P175.

    Google Scholar 

  90. Rötzer S, Fazel J, Seidl C, Frank A, Authnrieth M, Morgenstern A, et al. Fractionated locoregional alpha-radioimmunotherapy of bladder cancer in a nude mouse model. Eur J Nucl Med Mol Imaging 2010;37 Suppl 2:OP473.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Hospital Sant Pau, Autonomous University of Barcelona, Barcelona, Spain

    Ignasi Carrió

Authors
  1. Ignasi Carrió
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ignasi Carrió.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carrió, I. Current research in nuclear medicine and molecular imaging: highlights of the 23rd Annual EANM Congress. Eur J Nucl Med Mol Imaging 38, 378–399 (2011). https://doi.org/10.1007/s00259-010-1698-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1698-4

Keywords

Search

Navigation